K
Kelly Krohn
Researcher at Eli Lilly and Company
Publications - 35
Citations - 2171
Kelly Krohn is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Osteoporosis & Teriparatide. The author has an hindex of 17, co-authored 35 publications receiving 1843 citations. Previous affiliations of Kelly Krohn include University of Arizona.
Papers
More filters
Journal ArticleDOI
Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-Blind Study of 102 Postmenopausal Women With Distal Radial Fractures
Per Aspenberg,Harry K. Genant,Torsten Johansson,Antonio J. Nino,Kyoungah See,Kelly Krohn,Pedro A García-Hernández,Christopher P Recknor,Thomas A. Einhorn,Gail P Dalsky,Bruce H. Mitlak,Anke Fierlinger,Mark Lakshmanan +12 more
TL;DR: The shortened time to healing for teriparatide 20 µg compared with placebo still may suggest that fracture repair can be accelerated by teriparkinide, but this result should be interpreted with caution and warrants further study.
Journal ArticleDOI
Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial
Kenneth G. Saag,Jose R. Zanchetta,Jean-Pierre Devogelaer,Robert A. Adler,Richard Eastell,Kyoungah See,John H. Krege,Kelly Krohn,Margaret R. Warner +8 more
TL;DR: It is indicated that subjects with glucocorticoid-induced OP treated with teriparatide for 36 months had greater increases in BMD and fewer new vertebral fractures than subjects treated with alendronate.
Journal ArticleDOI
Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
Daniel H. Solomon,Stephen S. Johnston,Natalie N. Boytsov,Donna McMorrow,Joseph M. Lane,Kelly Krohn +5 more
TL;DR: Most patients suffering a hip fracture do not use osteoporosis medication in the subsequent year and treatment rates have worsened, so a retrospective, observational cohort study based on U.S. administrative insurance claims data for beneficiaries with commercial or Medicare supplemental health insurance is conducted.
Journal ArticleDOI
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Bente L. Langdahl,Fernando Marin,Elizabeth Shane,Harald Dobnig,Jose R. Zanchetta,Michael Maricic,Kelly Krohn,Kyoungah See,Margaret R. Warner +8 more
TL;DR: Among men and pre- and postmenopausal women with GIO, lumbar spine BMD increased more in patients receiving teriparatide compared with alendronate, and this was a multicenter, randomized, double-blind study.
Journal ArticleDOI
Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Tony M. Keaveny,Michael R. McClung,Xiaohai Wan,David L. Kopperdahl,Bruce H. Mitlak,Kelly Krohn +5 more
TL;DR: Non-linear finite element analysis of quantitative computed tomography scans from 48 women who had participated in a randomized, double-blind clinical trial comparing the effects of 18-month treatment of teriparatide 20 μg/d or alendronate 10mg/d found that, despite different compartmental volumetric BMD responses for these two treatments, no overall difference in change in femoral strength was detected.